Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219Barbara Melosky, Penelope Bradbury, Dongsheng Tu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapyPenelope A Bradbury, Donald G Morris, Garth Nicholas, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2020
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226Rosalyn A Juergens, Desiree Hao, Peter M Ellis, et al.Nature Communications|June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficienciesJohn Hilton, Karen Gelmon, Philippe L Bedard, et al.Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.Pageof 7